GRTX OTC
Galera Therapeutics, Inc.
1W: +16.6%
1M: +7.8%
3M: -6.9%
YTD: +313.7%
1Y: +279.8%
3Y: -96.5%
5Y: -99.0%
$17.15
Last traded 2026-08-03 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2024-05-03
Earliest Filing
2025-10-27
Latest Filing
partner: 4
acquirer: 2
investor: 2
target: 1
Counterparties (Filed by GRTX)
9 relationshipsCompanies named in GRTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Biossil Inc. | — | acquirer | Acquired all dismutase mimetic assets including avasopasem and rucosopasem from Galera Therapeutics, Inc. | 2025-10-27 | View |
| Biossil Inc. | — | acquirer | Acquired all rights, title, and interest in Galera Therapeutics' assets related to avasopasem and rucosopasem. | 2025-10-21 | View |
| Clarus IV Galera Royalty AIV, L.P. | CLAR | partner | Party to the Amended and Restated Purchase and Sale Agreement regarding royalty obligations. | 2025-10-21 | View |
| Clarus IV Galera Royalty AIV, L.P. | CLAR | investor | Purchaser in royalty agreement amendment | 2025-09-03 | View |
| Blackstone Life Sciences | BX | investor | Affiliated with Purchaser and successor to Clarus Ventures | 2025-09-03 | View |
| Nova Pharmaceuticals, Inc. | — | target | Target company acquired by Galera Therapeutics, Inc. in a merger transaction. | 2024-12-31 | View |
| Grape Merger Sub I, Inc. | — | partner | Wholly owned subsidiary of Galera used as a merger vehicle. | 2024-12-31 | View |
| Grape Merger Sub II, LLC | — | partner | Wholly owned subsidiary of Galera used as a merger vehicle. | 2024-12-31 | View |
| Equiniti Trust Company, LLC | — | partner | Rights Agent for the Stockholder Rights Agreement | 2024-05-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Material Agreement; Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Director C | Agreement Acquisition | View |
| 2026-07-31 | Unregistered Equity Sales; Regulation FD; Exhibits | View | |
| 2026-07-13 | Bylaws Amendment; Exhibits | View | |
| 2026-07-07 | Other Events | View | |
| 2026-05-19 | Other Events | View | |
| 2026-05-15 | Bylaws Amendment; Exhibits | View | |
| 2026-04-14 | Material Agreement; Unregistered Equity Sales; Change in Control; Regulation FD; Exhibits | Agreement | View |
| 2026-04-09 | Other Events | View | |
| 2026-04-03 | Other Events | View | |
| 2026-02-18 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2026-02-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-27 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-10-21 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-09-03 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-04-02 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-03-24 | Financial Statements and Exhibits | View | |
| 2025-02-25 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-12-31 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregi | Agreement Acquisition | View |
| 2024-12-20 | Other Events; Financial Statements and Exhibits | View | |
| 2024-10-18 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR